In 232 Italian adults with type 2 diabetes followed for 24 months, oral semaglutide delivered a mean HbA1c reduction of 0.8% and 5.7 kg body weight loss, with 44% achieving the composite target of HbA1c ≤7% plus ≥5% weight loss. Treatment persistence reached 68.5% at two years (mean 19.4 months). LDL and total cholesterol fell significantly, renal markers eGFR and UACR remained stable, and a notable finding emerged: non-breakfast pill administration independently predicted lower HbA1c (β = −0.32), suggesting timing optimization could meaningfully influence outcomes. Among the 31.5% who discontinued, switching to injectable GLP-1 agonists produced an additional HbA1c drop of 0.98%.
Oral semaglutide occupies a narrow pharmacological niche — a GLP-1 receptor agonist that sidesteps injection aversion but faces absorption constraints requiring strict fasting protocols. Two-year real-world persistence near 70% compares favorably to many oral diabetes agents and mirrors injectable GLP-1 data, addressing a persistent skepticism about adherence to its complex dosing requirements. The administration-timing finding is underappreciated clinically and warrants prospective investigation. Limitations are meaningful: retrospective single-center design, predominantly Italian cohort limiting generalizability, no placebo control, and modest sample size. The 5.7 kg weight loss, while meaningful metabolically, trails the 10–15 kg seen with injectable semaglutide in trials like SUSTAIN and STEP. Overall, this is confirmatory real-world evidence strengthening oral semaglutide's practical case, with the timing-effect observation as its most actionable novel signal.